OrbiMed Israel GP II, L.P.: insider trades.
OrbiMed Israel GP II, L.P. reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($16.1M) and 0 sales, across 1 company.
- Transactions
- 11
- Purchases (P)
- 3
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- OrbiMed Israel GP II, L.P.
Companies
| Company | Relationship | Transactions |
|---|---|---|
| ADARx Pharmaceuticals, Inc. (ADRX) | Director, TenPercentOwner | 11 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 564,187 | — | 14,025,280 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 300,249 | $17 | 14,325,529 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 7,127,019 | — | 7,127,019 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 1,333,975 | — | 8,460,994 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 513,067 | — | 8,974,061 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 256,448 | — | 9,230,509 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 769,601 | — | 13,461,093 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 2,000,962 | — | 12,691,492 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | C | 10,690,530 | — | 10,690,530 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 61,516 | $17 | 9,292,025 | Form 4 |
| 2026-09-28 | ADARx Pharmaceuticals, Inc. | P | 588,235 | $17 | 588,235 | Form 4 |
Questions
What stock did OrbiMed Israel GP II, L.P. buy or sell?
OrbiMed Israel GP II, L.P. reported 11 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 3 open-market purchases ($16.1M) and 0 sales, across 1 company.
Is OrbiMed Israel GP II, L.P. the same person as other filers with this name?
This page covers SEC CIK 1682090 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/orbimed-israel-gp-ii-l-p-1682090.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.